Abstract:Liver fibrosis is the hallmark of liver disease and occurs prior to the stages of cirrhosis and hepatocellular carcinoma. Any type of liver damage or inflammation can result in fibrosis. Fibrosis does not develop overnight, but rather as a result of the long-term action of injury factors. At present, however, there are no good treatment methods or specific drugs other than removing the pathogenic factors. Drug application is still limited, which means that drugs with good performance in vitro cannot achieve good therapeutic effects in vivo , owing to various factors such as poor drug targeting, large side effects and strong hydrophobicity. Hepatic stellate cells (HSCs) are the primary effector cells in liver fibrosis. The nano-drug delivery system is a new and safe drug delivery system that has many advantages which are widely used in the field of liver fibrosis. Drug resistance and side effects can be reduced when two or more drugs are used in combination drug delivery. Combination therapy of drugs with different targets has emerged as a novel approach to treating liver fibrosis, and the nano co-delivery system enhances the benefits of combination therapy. While nano co-delivery systems can maximise benefits while avoiding drug side effects, this is precisely the advantage of the nano co-delivery system. This review briefly described the pathogenesis and current treatment strategies, the different co-delivery systems of combination drugs in the nano delivery system, and targeting strategies for nano delivery systems on liver fibrosis therapy. Due to their superior performance, nano delivery systems and targeting drug delivery systems have received a lot of attention in the new drug delivery system. The new delivery systems offer a new pathway in the treatment of liver fibrosis, and it is believed that it can be a new treatment for fibrosis in the future. Nano co-delivery system of combination drugs and targeting strategies has proven the effectiveness of anti-fibrosis at the experimental level.

Targeted delivery of drugs for liver fibrosis.

Liver Fibrosis Therapy Based on Biomimetic Nanoparticles Which Deplete Activated Hepatic Stellate Cells.

Targeted Drug Delivery to Hepatic Stellate Cells for the Treatment of Liver Fibrosis

Nano-encapsulation of drugs to target hepatic stellate cells: Toward precision treatments of liver fibrosis

Insights on drug and gene delivery systems in liver fibrosis

Nanoparticles Targeting Hepatic Stellate Cells for the Treatment of Liver Fibrosis

Novel Nano-Based Drug Delivery Systems Targeting Hepatic Stellate Cells in the Fibrotic Liver

Liver Fibrosis: Therapeutic Targets and Advances in Drug Therapy

Combination therapy based on targeted nano drug co-delivery systems for liver fibrosis treatment: a review

Precise Cell Therapy for Liver Fibrosis: Endothelial Cell and Macrophage Therapy

Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets

Hepatic fibrosis: From bench to bedside

Clinical Advancements in the Targeted Therapies against Liver Fibrosis

Hepatic Stellate Cells as a Target for the Treatment of Liver Fibrosis

Targeting Hepatic Stellate Cells for the Treatment of Liver Fibrosis by Natural Products: Is It the Dawning of a New Era?

Cyclic Arg-Gly-Asp Peptide-Labeled Liposomes for Targeting Drug Therapy of Hepatic Fibrosis in Rats

Delivery Strategy to Enhance the Therapeutic Efficacy of Liver Fibrosis via Nanoparticle Drug Delivery Systems

Current and emerging pharmacotherapeutic interventions for the treatment of liver fibrosis

Nanotechnology in Drug Delivery for Liver Fibrosis.

Strategies Targeting the Innate Immune Response for the Treatment of Hepatitis C Virus-Associated Liver Fibrosis

Hepatic stellate cells: a target for the treatment of liver fibrosis